Literature DB >> 11085365

Pharmacokinetic prediction of the ocular absorption of an instilled drug with ophthalmic viscous vehicle.

H Sasaki1, K Yamamura, T Mukai, K Nishida, J Nakamura, M Nakashima, M Ichikawa.   

Abstract

We previously developed an in vivo pharmacokinetic model that accounts for the corneal diffusion in albino rabbits and predicts the concentration of beta-blockers in the anterior segments. The purpose of this study is to pharmacokinetically predict the ocular absorption and characterize the systemic absorption of instilled drug with ophthalmic viscous vehicle to assist in its design and evaluation. Tilisolol and carboxymethylcellulose sodium salt (CMC) were used as the model ophthalmic drug and viscous polymer, respectively. After instillation of tilisolol with CMC vehicle in rabbits, the disposition of the drug in tear fluid, aqueous humor, and plasma were determined by HPLC. The ocular and systemic absorption were analyzed by a mathematical model including a diffusion process and a two-compartment model with first-order absorption, respectively. CMC vehicle increased the area under the concentration-time curve (AUC) of tilisolol in the tear fluid and aqueous humor and slightly reduced the AUC in plasma. The concentrations of tilisolol in the aqueous humor after instillation with CMC vehicle were accurately predicted from the tear concentrations by using the in vivo ocular pharmacokinetic model. CMC vehicle improved the ocular delivery of tilisolol.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085365     DOI: 10.1248/bpb.23.1352

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation.

Authors:  L David Waterbury; Danielle Galindo; Linda Villanueva; Cathy Nguyen; Milan Patel; Lisa Borbridge; Mayssa Attar; Rhett M Schiffman; David A Hollander
Journal:  J Ocul Pharmacol Ther       Date:  2011-02-25       Impact factor: 2.671

2.  Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.

Authors:  Chengyun Wang; Huiyuan Hou; Kaihui Nan; Michael J Sailor; William R Freeman; Lingyun Cheng
Journal:  Exp Eye Res       Date:  2014-11-05       Impact factor: 3.467

3.  Ocular pharmacokinetics of 0.45% ketorolac tromethamine.

Authors:  Mayssa Attar; Rhett Schiffman; Lisa Borbridge; Quinn Farnes; Devin Welty
Journal:  Clin Ophthalmol       Date:  2010-12-01

4.  Physiologically Based Pharmacokinetic Model to Support Ophthalmic Suspension Product Development.

Authors:  Maxime Le Merdy; Ming-Liang Tan; Andrew Babiskin; Liang Zhao
Journal:  AAPS J       Date:  2020-01-06       Impact factor: 4.009

5.  Ex vivo corneal epithelial wound healing following exposure to ophthalmic nonsteroidal anti-inflammatory drugs.

Authors:  Keping Xu; Mark McDermott; Linda Villanueva; Rhett M Schiffman; David A Hollander
Journal:  Clin Ophthalmol       Date:  2011-02-28

6.  The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery.

Authors:  Ji Won Jung; Byung Hoon Chung; Eung Kweon Kim; Kyoung Yul Seo; Tae-im Kim
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.